These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32621327)

  • 21. Benefits of dual-release hydrocortisone treatment on central adiposity and health-related quality of life in secondary adrenal insufficiency.
    Gasco V; Giannelli J; Campioni L; Arvat E; Ghigo E; Grottoli S; Maccario M; Giordano R
    J Endocrinol Invest; 2023 Mar; 46(3):587-597. PubMed ID: 36251244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is physiological glucocorticoid replacement important in children?
    Porter J; Blair J; Ross RJ
    Arch Dis Child; 2017 Feb; 102(2):199-205. PubMed ID: 27582458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia.
    Rensen N; Gemke RJ; van Dalen EC; Rotteveel J; Kaspers GJ
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD008727. PubMed ID: 29106702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mortality Risk in Patients With Adrenal Insufficiency Using Prednisolone or Hydrocortisone: A Retrospective Cohort Study.
    Ngaosuwan K; Johnston DG; Godsland IF; Cox J; Majeed A; Quint JK; Oliver N; Robinson S
    J Clin Endocrinol Metab; 2021 Jul; 106(8):2242-2251. PubMed ID: 33993277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapy options for adrenal insufficiency and recommendations for the management of adrenal crisis.
    Nowotny H; Ahmed SF; Bensing S; Beun JG; Brösamle M; Chifu I; Claahsen van der Grinten H; Clemente M; Falhammar H; Hahner S; Husebye E; Kristensen J; Loli P; Lajic S; Reisch N;
    Endocrine; 2021 Mar; 71(3):586-594. PubMed ID: 33661460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of different glucocorticoid replacement schedules on bone turnover and insulin sensitivity in patients with adrenal insufficiency.
    Suliman AM; Freaney R; Smith TP; McBrinn Y; Murray B; McKenna TJ
    Clin Endocrinol (Oxf); 2003 Sep; 59(3):380-7. PubMed ID: 12919163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secondary adrenal insufficiency: from the physiopathology to the possible role of modified-release hydrocortisone treatment.
    Paragliola RM; Corsello SM
    Minerva Endocrinol; 2018 Jun; 43(2):183-197. PubMed ID: 28750490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison's disease.
    Giordano R; Guaraldi F; Marinazzo E; Fumarola F; Rampino A; Berardelli R; Karamouzis I; Lucchiari M; Manetta T; Mengozzi G; Arvat E; Ghigo E
    Endocrine; 2016 Feb; 51(2):360-8. PubMed ID: 26184416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal glucocorticoid therapy.
    Debono M; Ross RJ
    Endocr Dev; 2011; 20():173-180. PubMed ID: 21164270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal glucocorticoid replacement in adrenal insufficiency.
    Øksnes M; Ross R; Løvås K
    Best Pract Res Clin Endocrinol Metab; 2015 Jan; 29(1):3-15. PubMed ID: 25617168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Modified-release hydrocortisone for glucocorticoid deficiency].
    Nowotny H; Reisch N
    Internist (Berl); 2020 Jun; 61(6):565-572. PubMed ID: 32394073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydrocortisone replacement in disorders of sex development.
    Blankenstein O
    Endocr Dev; 2014; 27():160-71. PubMed ID: 25247653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency.
    Nilsson AG; Marelli C; Fitts D; Bergthorsdottir R; Burman P; Dahlqvist P; Ekman B; Engström BE; Olsson T; Ragnarsson O; Ryberg M; Wahlberg J; Lennernäs H; Skrtic S; Johannsson G
    Eur J Endocrinol; 2014 Sep; 171(3):369-77. PubMed ID: 24944332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy.
    Debono M; Ross RJ; Newell-Price J
    Eur J Endocrinol; 2009 May; 160(5):719-29. PubMed ID: 19168600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Usage of continuous glucose monitoring (CGM) for detecting an unrecognized hypoglycemia and management of glucocorticoid replacement therapy in adult patients with central hypoadrenalism.
    Watanabe T; Ozawa A; Ishii S; Tomaru T; Shibusawa N; Saito T; Yamada E; Horiguchi K; Nakajima Y; Matsumoto S; Yoshino S; Katano-Toki A; Hashimoto K; Mori M; Okada S; Satoh T; Yamada M
    Endocr J; 2018 May; 65(5):547-556. PubMed ID: 29618670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic comorbidities of adrenal insufficiency: Focus on steroid replacement therapy and chronopharmacology.
    Guarnotta V; Amodei R; Giordano C
    Curr Opin Pharmacol; 2021 Oct; 60():123-132. PubMed ID: 34416524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patients with adrenal insufficiency have cardiovascular features associated with hypovolemia.
    Esposito D; Bobbio E; Di Fraia R; Mone P; Accardo G; De Bellis A; Iorio S; Esposito K; Marfella R; Johannsson G; Ragnarsson O; Pasquali D
    Endocrine; 2020 Nov; 70(2):412-420. PubMed ID: 32813212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improving glucocorticoid replacement profiles in adrenal insufficiency.
    Choudhury S; Lightman S; Meeran K
    Clin Endocrinol (Oxf); 2019 Sep; 91(3):367-371. PubMed ID: 31017681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Towards the tailoring of glucocorticoid replacement in adrenal insufficiency: the Italian Society of Endocrinology Expert Opinion.
    Isidori AM; Arnaldi G; Boscaro M; Falorni A; Giordano C; Giordano R; Pivonello R; Pozza C; Sbardella E; Simeoli C; Scaroni C; Lenzi A;
    J Endocrinol Invest; 2020 May; 43(5):683-696. PubMed ID: 31773582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hydrocortisone Dose Influences Pain, Depressive Symptoms and Perceived Health in Adrenal Insufficiency: A Randomized Controlled Trial.
    Werumeus Buning J; Brummelman P; Koerts J; Dullaart RP; van den Berg G; van der Klauw MM; Sluiter WJ; Tucha O; Wolffenbuttel BH; van Beek AP
    Neuroendocrinology; 2016; 103(6):771-8. PubMed ID: 26646751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.